ClinicalTrials.gg
CompletedNCT06115356ViDOUpdated Nov 7, 2023

Hypovitaminosis D and "Metabolic" Inflammatory Status in Patients With Obesity

An observational study in Hypovitaminosis D and Obesity, sponsored by University of Trieste. Completed at 1 site in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-11-07.

Sponsored by University of Trieste · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
208
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Since obesity is related to systemic chronic inflammatory status and hypovitaminosis D, the study aimed to assess the incidence of hypovitaminosis D in obese patients and the correlations between vitamin D levels, inflammation indices, and bioimpedance measures.

A retrospective study was conducted on a cohort of obese patients. The inflammation-based prognostic scores, diagnosis of liver fibrosis, systemic inflammatory indices, and bioimpedance measures were analyzed. The linear relationship between vitamin D levels and continuous variables was assessed through the Spearman correlation coefficient, and to determine significant predictors of vitamin D levels a stepwise multiple linear regression was used.

Read the detailed description

Introduction Obesity is a major health problem related to a cluster of chronic metabolic disorders and is associated with increased overall morbidity and mortality. Several studies proved that obesity is linked to a low grade of systemic chronic inflammatory status, considering the adipose tissue the largest metabolically active organ with endocrine, inflammatory, and immunological functions.

The "metabolic" inflammatory process leads to the release of inflammatory cytokines with subsequent systemic effects on insulin-sensitive organs, such as the liver which markedly suffers from the systemic proinflammatory environment. Vitamin D (25(OH)D) plays a key role in the regulation of mineral homeostasis by binding the vitamin D receptors, leading to an adequate calcium level to promote skeletal health. Furthermore, vitamin D has anti-inflammatory and immunoregulatory functions. It is an indispensable nutritive component that regulates the inflammatory microenvironment through several mechanisms such as the up-regulation of Mitogen-activated protein kinases (MAPKs) and inhibition of Nuclear Factor-Kappa B (NF-Kb) signaling pathways.

A low level of vitamin D in the visceral adipose tissue (VAT) induces more lipogenesis and less lipolysis promoting fat storage and obesity. The prevalence of vitamin D deficiency is 24% and 35% higher in overweight and obese people, respectively, compared to the general population. Many hypotheses have been proposed to explain the inverse correlation between Vitamin D and obesity:1) the storage of this fatsoluble nutrient in the exceeded VAT; 2) the higher plasma dilution of the Vitamin D in the obese patient compared to the normal-weight population; 3) the reduced sun exposure due to the stigma of obesity; 4) the presence of metabolic syndrome or type 2 diabetes that often co-exist with obesity; 5) molecular interactions between Vitamin D and pro-inflammatory cytokines.

Thus, hypovitaminosis D, inflammation, and obesity are three pathological conditions closely linked. In the literature, data explaining this relationship are still inconsistent, but crosstalk based on molecular signals exists.

On this basis, patients with obesity could be a high-achieving biological model helping to clarify the noncalcemic effects of vitamin D in regulating inflammation.

The first aim of the study is to assess the incidence of hypovitaminosis D in a cohort of obese patients; secondly, our purpose is to evaluate the correlation between hypovitaminosis D and inflammation's indices: inflammation-based prognostic scores, ferritin, C-reactive protein (CRP), inflammation grade on liver biopsy, and bioimpedance measures.

Materials and Methods This monocentric retrospective cohort study is based on a prospective database of consecutive obese patients referred to the General Surgery Department at Cattinara University Hospital in Trieste, Italy, between January 2018 and June 2021.

Patients were divided into three groups according to 25(OH) D levels: deficiency was defined as 25(OH) D levels ≤ 20 ng/mL, insufficiency between 21 and 29 ng/mL, and normal ≥ 30 ng/mL. The cohort was divided into three classes of obesity, according to BMI: grade I obesity 30.0-34.9 kg/m2; grade II obesity, 35.0-39.9 kg/m2; grade III obesity ≥40.0 kg/m2.

Measurements of body composition were conducted with Bioelectrical Impedance Analysis (BIA) technique, asking the participants to stand on the device barefoot to complete the analysis. Among all parameters, BMI, phase angle (PhA), total body water (TBW), extracellular (ECW) and intracellular water (ICW), body fat index, and fat and muscular mass were recorded. The PhA cutoff was not clearly defined in the literature, a value between 7.0 and 6.0 are found to be optimal in adulthood. Before surgery, the systemic inflammatory indices recorded were ferritin plasma level, CRP, and the following inflammation-based prognostic scores were considered for analysis: Glasgow Prognostic Score/modified Glasgow Prognostic Score (GPS/mGPS), Prognostic Nutritional Index (PNI), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte ratio (PLR), Lymphocyte-to-monocyte ratio (LMR), Systemic immune inflammation index (SII). CRP values≥ 5 mg/dL were considered pathological.

During the bariatric surgery, a liver biopsy was performed and analyzed by a single experienced pathologist blinded to all clinical and laboratory parameters. Patients with other forms of chronic liver disease, including suspected/confirmed hepatocellular carcinoma, alcoholic liver disease (>25 g/day alcohol consumption), or known hepatitis B virus, hepatitis C virus, and human immunodeficiency virus positivity were excluded. The histological diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis according to Kleiner-Brunt classification was detected. NASH was defined as a total no alcoholic fatty liver disease (NAFLD) activity score ≥ 5.

The study was conducted according to the STROBE Guidelines.

Statistical Analysis Continuous normal variables were expressed as mean ± standard deviation (SD); continuous non-normal variables as median and range (25 percentile-75 percentile). The Shapiro-Wilk test was performed to assess normality. Kruskal-Wallis non-parametric test was performed to identify differences in continuous variables of interest among the three groups. Post-hoc tests, and pair-wise comparisons using Mann-Whitney test, were conducted and corrected using the Holm method Categorical variables were expressed as absolute frequency and percentages and compared with Chi-Squared or Fisher-Exact Test when appropriate. The linear relationship between 25(OH) D levels and study continuous variables was assessed through the Spearman correlation coefficient. The most significant individual variables have been incorporated into a stepwise multiple linear regression (stepwise selection based on Akaike information criterion) to determine significant predictors of 25(OH) D levels. Two multiple linear regression analysis models were performed: 1) to estimate the predictive values of the bioelectrical impedance analysis and 2) to estimate the predictive values of inflammatory parameters. Beta and the standard error of Beta were reported as linear model results. P-Values ≤ 0.05 were considered statistically significant.

Data were analyzed using the R Statistical Software.

02

Conditions studied

  • Hypovitaminosis D
  • Obesity

Keywords

  • Hypovitaminosis D
  • Obesity
  • Bariatric surgery
  • Inflammation
03

In context

Vitamin D Deficiency

801 studies on the registry are indexed under Vitamin D Deficiency; 60 are open to participants now.

This study's enrollment of 208 is above the median of 138 across 185 observational studies indexed under Vitamin D Deficiency.

Browse Vitamin D Deficiency studies →

Lead sponsor

University of Trieste is the lead sponsor of 39 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with obesity eligible for bariatric surgery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • > 35 Eligible for bariatric surgery according to the current international guidelines (IFSO guidelines)

Exclusion criteria

Exclusion Criteria:

  • Patients affected by active liver viral infection
  • Patient alcohol or drug addicted
  • Incompetent patients
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
208 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • Diagnostic testVitamin D Plasma Level

    Blood test measured in ng/ml

  • Diagnostic testBioelectrical Impedance Analysis (BIA) technique

    Measurements of body composition were conducted with Bioelectrical Impedance Analysis (BIA) technique, asking the participants to stand on the device barefoot to complete the analysis. Among all parameters, BMI, phase angle (PhA), total body water (TBW), extracellular (ECW) and intracellular water (ICW), body fat index, and fat and muscular mass were recorded.

  • Diagnostic testFerritin

    Ferritin plasma levels were measured in μg/L

  • Diagnostic testC reactive protein (CRP)

    CRP plasma levels were measured in mg/L

  • Diagnostic testInflammation-based prognostic scores

    Glasgow Prognostic Score/modified Glasgow Prognostic Score (GPS/mGPS), Prognostic Nutritional Index (PNI), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte ratio (PLR), Lymphocyte-to-monocyte ratio (LMR), Systemic immune-inflammation index (SII) were calculated using blood test results

  • OtherLiver biopsy

    A liver biopsy was used to study nonalcoholic steatohepatitis (NASH) and fibrosis according to the Kleiner-Brunt classification

06

What researchers measure

Primary outcomes

  1. Vitamine D plasma level in patients with obesity

    To assess the incidence of hypovitaminosis D in a cohort of patients with obesity

    Time frame: enrollment time

Secondary outcomes

  1. Vitamin D plasma level and systemic inflammation

    Correlation between inflammation-based prognostic scores, ferritin, C-reactive protein (CRP) and vitamine D levels

    Time frame: enrollment time

  2. Vitamin D plasma level and liver fibrosis/inflammation

    Correlation between Vitamin D plasma level and liver fibrosis/inflammation

    Time frame: enrollment time

  3. Vitamine D plasma level and bioimpedance parameters

    Correlation between Vitamine D level and bioimpedance parameters (BMI, phase angle (PhA), total body water (TBW), extracellular (ECW) and intracellular water (ICW), body fat index, and fat and muscular mass)

    Time frame: enrollment time

07

Study locations

1 site
  • Silvia Palmisano
    Trieste, 34100, Italy
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06115356
Lead sponsor
University of Trieste
Responsible party
Silvia Palmisano (Associate professor, University of Trieste) — Principal investigator
First posted
Nov 3, 2023
Start date
Jan 1, 2018
Primary completion
Jun 30, 2021
Completion
Jun 30, 2021
Last update
Nov 7, 2023

Study contacts

Silvia Palmisano, MD
principal investigator · University of Trieste

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion